NASDAQ:ALLK - Allakos Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$37.68 +2.52 (+7.17 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$35.16
Today's Range$34.66 - $37.68
52-Week Range$26.00 - $65.48
Volume304,800 shs
Average Volume369,132 shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLK
CUSIPN/A
CIKN/A
Phone650-597-5002

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$1.59 billion
Next Earnings Date2/28/2019 (Estimated)
OptionableNot Optionable

Allakos (NASDAQ:ALLK) Frequently Asked Questions

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

How were Allakos' earnings last quarter?

Allakos Inc (NASDAQ:ALLK) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.10. View Allakos' Earnings History.

When is Allakos' next earnings date?

Allakos is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Allakos.

What price target have analysts set for ALLK?

3 brokers have issued 1 year target prices for Allakos' stock. Their predictions range from $31.00 to $53.00. On average, they expect Allakos' stock price to reach $42.00 in the next year. This suggests a possible upside of 11.5% from the stock's current price. View Analyst Price Targets for Allakos.

What is the consensus analysts' recommendation for Allakos?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allakos.

Has Allakos been receiving favorable news coverage?

News stories about ALLK stock have trended somewhat positive on Saturday, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a news impact score of 1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

Who are Allakos' key executives?

Allakos' management team includes the folowing people:
  • Dr. Robert Alexander, Pres, CEO & Director (Age 49)
  • Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)
  • Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)
  • Dr. Ruby Casareno Ph.D., VP of Technical Operations
  • Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56)

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

When did the company's lock-up period expire?

Allakos' lock-up period expired on Tuesday, January 15th. Allakos had issued 7,133,333 shares in its IPO on July 19th. The total size of the offering was $128,399,994 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.90%), Partner Fund Management L.P. (1.47%), Jennison Associates LLC (0.70%), Orbimed Advisors LLC (0.42%), Geode Capital Management LLC (0.29%) and Northern Trust Corp (0.27%). Company insiders that own Allakos stock include Daniel Janney, John P Mckearn and Venture Fund (Ohi Rivervest II. View Institutional Ownership Trends for Allakos.

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Orbimed Advisors LLC, KAMES CAPITAL plc, Partner Fund Management L.P., MetLife Investment Advisors LLC, Victory Capital Management Inc., Geode Capital Management LLC and Millennium Management LLC. Company insiders that have sold Allakos company stock in the last year include John P Mckearn and Venture Fund (Ohi Rivervest II. View Insider Buying and Selling for Allakos.

Which major investors are buying Allakos stock?

ALLK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Citigroup Inc., Bank of New York Mellon Corp, New York State Common Retirement Fund, Rhumbline Advisers, Virtus ETF Advisers LLC and Northern Trust Corp. Company insiders that have bought Allakos stock in the last two years include Daniel Janney and Venture Fund (Ohi Rivervest II. View Insider Buying and Selling for Allakos.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $37.68.

How big of a company is Allakos?

Allakos has a market capitalization of $1.59 billion. Allakos employs 44 workers across the globe.

What is Allakos' official website?

The official website for Allakos is http://www.allakos.com.

How can I contact Allakos?

Allakos' mailing address is 75 SHOREWAY ROAD SUITE A, SAN CARLOS CA, 94070. The company can be reached via phone at 650-597-5002 or via email at [email protected]


MarketBeat Community Rating for Allakos (NASDAQ ALLK)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Allakos and other stocks. Vote "Outperform" if you believe ALLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Featured Article: Backdoor Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel